Jia F Lin1, Pascal K C Jonker1, Michelle Cunich2, Stanley B Sidhu3, Leigh W Delbridge3, Anthony R Glover3, Diana L Learoyd4, Ahmad Aniss3, Schelto Kruijff2, Mark S Sywak5. 1. University of Groningen, University Medical Center Groningen, Department of Surgery, the Netherlands. 2. Boden Institute, The University of Sydney School of Medicine, NSW, Australia. 3. Department of Endocrine and Oncology Surgery, The University of Sydney, NSW, Australia. 4. Department of Endocrinology, The University of Sydney, NSW, Australia. 5. Department of Endocrine and Oncology Surgery, The University of Sydney, NSW, Australia. Electronic address: marksywak@nebsc.com.au.
Abstract
BACKGROUND: Papillary thyroid microcarcinoma is a subtype of thyroid cancer that may be managed with active surveillance rather than immediate surgery. Active surveillance decreases complication rates and may decrease health care costs. This study aims to analyze complication rates of thyroid surgery, papillary thyroid microcarcinoma recurrence, and survival rates. Additionally, the costs of surgery versus hypothetic active surveillance for papillary thyroid microcarcinoma are compared in an Australian cohort. METHODS: Papillary thyroid microcarcinoma patients were included from a prospectively collected surgical cohort of patients treated for papillary thyroid cancer between 1985 and 2017. The primary outcomes were the complications of thyroid surgery, recurrence-free survival, overall survival, and cost of surgical treatment and active surveillance. RESULTS: In a total of 349 patients with papillary microcarcinoma with a median age of 48 years (range, 18-90 years), the permanent operative complications rate was 3.7%. Postoperative radioactive iodine did not decrease recurrence-free survival (P = .3). The total cost of surgical treatment was $10,226 Australian dollars, whereas hypothetic active surveillance was at a yearly cost of $756 Australian dollars. Estimated cost of surgical papillary thyroid microcarcinoma treatment was equivalent to the cost of 16.2 years of active surveillance. CONCLUSION: Surgery may have a long-term economic advantage for younger Australian patients with papillary thyroid microcarcinoma who are likely to require more than 16.2 years of follow-up in an active surveillance scheme.
BACKGROUND:Papillary thyroid microcarcinoma is a subtype of thyroid cancer that may be managed with active surveillance rather than immediate surgery. Active surveillance decreases complication rates and may decrease health care costs. This study aims to analyze complication rates of thyroid surgery, papillary thyroid microcarcinoma recurrence, and survival rates. Additionally, the costs of surgery versus hypothetic active surveillance for papillary thyroid microcarcinoma are compared in an Australian cohort. METHODS:Papillary thyroid microcarcinomapatients were included from a prospectively collected surgical cohort of patients treated for papillary thyroid cancer between 1985 and 2017. The primary outcomes were the complications of thyroid surgery, recurrence-free survival, overall survival, and cost of surgical treatment and active surveillance. RESULTS: In a total of 349 patients with papillary microcarcinoma with a median age of 48 years (range, 18-90 years), the permanent operative complications rate was 3.7%. Postoperative radioactive iodine did not decrease recurrence-free survival (P = .3). The total cost of surgical treatment was $10,226 Australian dollars, whereas hypothetic active surveillance was at a yearly cost of $756 Australian dollars. Estimated cost of surgical papillary thyroid microcarcinoma treatment was equivalent to the cost of 16.2 years of active surveillance. CONCLUSION: Surgery may have a long-term economic advantage for younger Australian patients with papillary thyroid microcarcinoma who are likely to require more than 16.2 years of follow-up in an active surveillance scheme.
Authors: A Ríos; M A Rodríguez; J A Puñal; P Moreno; E Mercader; E Ferrero; J Ruiz-Pardo; M A Morlán; J Martín; M Durán-Poveda; J M Bravo; D Casanova; M P Salvador Egea; N M Torregrosa; A Exposito-Rodríguez; G Martínez-Fernández; A M Carrión; O Vidal; F Herrera; G Ruiz-Merino; J M Rodríguez Journal: Langenbecks Arch Surg Date: 2022-10-17 Impact factor: 2.895
Authors: Ian D Hay; Robert A Lee; Suneetha Kaggal; John C Morris; Marius N Stan; M Regina Castro; Vahab Fatourechi; Geoffrey B Thompson; J William Charboneau; Carl C Reading Journal: J Endocr Soc Date: 2020-09-15
Authors: Claudio R Cernea; Leandro Luongo Matos; Cecília Eugênio; Giovanna Mattos Ferreira; Yasmin Sa Cerqueira; Ana Kober N Leite; Felipe A B Vanderlei; Dorival de Carlucci; Renato N Gotoda; Flávio C Hojaij; Vergilius J F Araújo-Filho Journal: Curr Oncol Rep Date: 2022-01-21 Impact factor: 5.075
Authors: Min Ji Jeon; Yea Eun Kang; Jae Hoon Moon; Dong Jun Lim; Chang Yoon Lee; Yong Sang Lee; Sun Wook Kim; Min-Hee Kim; Bo Hyun Kim; Ho-Cheol Kang; Minho Shong; Sun Wook Cho; Won Bae Kim Journal: Endocrinol Metab (Seoul) Date: 2021-03-23